On July 16, 2012, under the active promotion of Zhang Gehua, Director of the Department of Otolaryngology-Head and Neck Surgery, and with the cooperation of relevant departments of our hospital, two patients with hearing impairment (one with congenital bilateral microtia with hearing impairment and one with congenital cleft lip and palate with bilateral chronic suppurative otitis media) were operated by Dr. Zeng Xiangli’s audiological testing team after a systematic audiological evaluation was completed before the surgery. The surgery was performed by Dr. Li Peng and Dr. Li Yongqi, Deputy Chief of the Department of Otolaryngology and Head and Neck Surgery. The first bone conduction Baha implantation surgery in South China was completed, and a total of two cases were successfully completed in our hospital during the same period. This not only indicates that Baha implantation technology has been officially introduced to China, but also means that Baha surgery has been successfully performed in South China, which will benefit more people with conductive, mixed and unilateral deafness. Up to now, less than 30 cases of this type of surgery have been performed in China. It also marks a new level of ear microsurgery technology in our hospital. Baha, or Bone Anchored Hearing Aid (Baha), is a device for treating deafness through bone conduction, which requires surgical implantation. Baha is currently being used to help patients with chronic otitis media, congenital external atresia and unilateral deafness who cannot use conventional hearing aids, and is one of the promising artificial hearing technologies available internationally today. This system requires surgical implantation and conducts sound to the inner ear through the bone conduction rather than the middle ear. As of today, Baha has more than 80,000 beneficiaries worldwide as the best treatment option for conductive and mixed hearing loss. According to Cochlear, global experience shows that Baha is a low-risk procedure that can usually be performed on an outpatient basis without the risk of further hearing loss. In the past, there was always a percentage of deaf patients who were not suitable for hearing aids or cochlear implants, such as those with abnormalities in the outer or middle ear, or those with only one functioning ear. Now this group of patients can have their hearing problems solved with this new technology. It is satisfying to know that Baha can be tried on before surgery and can predict post-operative clinical outcomes, thus making “providing better sound function and speech understanding” an assessable, perceptible and predictable option for the average hearing impaired person. Children can also be implanted with Baha when they have sufficient bone volume and quality, or they can choose to wear the Baha soft band, which provides a new hearing solution at the optimal age for their speech development. The new implantable bone-conduction hearing solution, Baha, was developed by Cochlear Australia and introduced to China in 2010. The latest Baha bone-conduction hearing implant, BI300, was approved by the State Drug Administration on May 4, thus making this complete technology officially approved for clinical use. The first Baha surgery in South China has been successfully carried out in the Department of Otolaryngology of the Third Affiliated Hospital of Sun Yat-sen University to serve more hearing impaired patients in the future. Through Baha, they will get clearer sound and higher quality of life.